Cell Cycle· 2026Q1· Review
The role of fibronectin in the tumor microenvironment – implications for immunotherapy
- 0citations
- Q1SCImago
- 2026year
Short summary
Oncofetal fibronectin (FN) variants, specifically those with EDA/EDB domains, are highly expressed in tumors and promote angiogenesis, metastasis, and immune resistance by driving EMT and forming pre-metastatic niches.
AI-generated from the title and abstract; the full text is not read.
Key points
- Oncofetal fibronectin (FN) variants with EDA/EDB domains are tumor-specific and promote oncogenesis.
- FN drives key tumor progression mechanisms: angiogenesis, EMT, pre-metastatic niche formation, and immunosuppression.
- FN variants are potential biomarkers and therapeutic targets in breast cancer, ovarian cancer, and glioblastoma.
- Novel stromal therapies (ADCs, immunocytokines) may overcome resistance to standard immunotherapy by targeting FN.
AI-generated from the title and abstract; the full text is not read.
Abstract
Contemporary models of tumor progression highlight the key role of the tumor microenvironment (TME) and the extracellular matrix (ECM) in regulating angiogenesis, metastasis, and immune resistance. Among ECM components, oncofetal fibronectin (FN) isoforms containing the EDA and EDB domains are of particular interest because they are highly expressed in solid tumors but absent from normal adult tissues. This review article synthesizes current data on the pathophysiological functions of FN variants in oncogenesis. Particular attention was paid to their role in pathological vascular remodeling, the induction of epithelial-mesenchymal transition (EMT), the formation of pre-metastatic niches, and the generation of an immunosuppressive environment. The study also critically assesses the clinical significance of FN as a biomarker and a potential target for new therapies in breast cancer, ovarian cancer and glioblastoma. The prospects for the use of innovative stromal strategies - including antibody-drug conjugates (ADCs) and immunocytokines - to overcome resistance to standard immunotherapy are also highlighted.
The authors' abstract, as published at the source. Cell Cycle, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Immunology and Allergy
Immunology and AllergyMedicine